Ann: Notice of Investor Call and Presentation, page-132

The question regarding which additional indication Invex will choose is interesting. From a patent protection perspective:

1. EU Patent covers IIH Only
2. US Patent covers a swathe of Intracranial pressure related conditions including idiopathic intracranial hypertension (IIH), secondary pseudotumour cerebri, hydrocephalus, normal pressure hydrocephalus, raised intracranial pressure secondary to a brain tumour, meningitis, brain trauma, brain injury, and venous sinus thrombosis.

Invex have hinted that they have money left over, so I suspect they will choose one or more of the following:

• IIHWOP due to the fact that the mechanism of action and disease profile is similar to IIH, so no reformulation needs to be completed. This would be my preferred option to keep their cash buffer up especially since Biotech companies have a tendency to underbudget.
• Orphan Drug Disease e.g. Moderate to Severe TBI given the additional protections it confers. Peptron have already published preclinical data in Traumatic Brain Injury with PT320.
• Spaceflight associated neuro-ocular syndrome (SANS): Given the upcoming mission to Mars and NASA interest, and the recent comercialisation of space travel.